Canada - TSX:AEZS - CA0079756007 - Common Stock
The current stock price of AEZS.CA is 4.12 CAD. In the past month the price decreased by -18.25%. In the past year, price decreased by -66.34%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
EPRX.CA | EUPRAXIA PHARMACEUTICALS INC | N/A | 425.04M | ||
EDT.CA | SPECTRAL MEDICAL INC | N/A | 403.12M | ||
FRX.CA | FENNEC PHARMACEUTICALS INC | N/A | 342.31M | ||
HBP.CA | HELIX BIOPHARMA CORP | N/A | 183.31M | ||
BLU.CA | BLUENERGIES LTD | N/A | 171.18M | ||
MSCL.CA | SATELLOS BIOSCIENCE INC | N/A | 80.27M | ||
MDNA.CA | MEDICENNA THERAPEUTICS CORP | N/A | 78.41M | ||
NRX.CA | NUREXONE BIOLOGIC INC | N/A | 76.69M | ||
COV.CA | COVALON TECHNOLOGIES LTD | 25.12 | 55.11M | ||
SVA.CA | SERNOVA BIOTHERAPEUTICS INC | N/A | 44.58M | ||
MBX.CA | MICROBIX BIOSYSTEMS INC | N/A | 37.74M | ||
BCT.CA | BRIACELL THERAPEUTICS CORP | N/A | 32.30M |
COSCIENS Biopharma Inc is a CA-based company operating in Biotechnology industry. The company is headquartered in Toronto, Ontario. COSCIENS Biopharma Inc., formerly Aeterna Zentaris Inc., is a specialty biopharmaceutical company engaged in the development and commercialization of a diverse portfolio of pharmaceutical and diagnostic products, including those focused on areas of unmet medical need. Its lead product, macimorelin (Macrilen; Ghryvelin), is an oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). The firm is also engaged in the development of therapeutic assets and proprietary extraction technology, which is applied to the production of active ingredients from renewable plant resources used in cosmeceutical products (i.e., oat beta glucan and avenanthramides, which are found in skincare product brands like Aveeno and Burt’s Bees formulations) and being developed as potential nutraceuticals and/or pharmaceuticals.
AETERNA ZENTARIS INC
C/O Norton Rose Fulbright Canada Llp, 222 Bay Street, Suite 3000, Po Box 53
TORONTO ONTARIO 29486 CA
CEO: Klaus Paulini
Employees: 12
Phone: 18439003201
The current stock price of AEZS.CA is 4.12 CAD. The price increased by 1.48% in the last trading session.
The exchange symbol of AETERNA ZENTARIS INC is AEZS and it is listed on the Toronto Stock Exchange exchange.
AEZS.CA stock is listed on the Toronto Stock Exchange exchange.
AETERNA ZENTARIS INC (AEZS.CA) has a market capitalization of 15.49M CAD. This makes AEZS.CA a Nano Cap stock.
AETERNA ZENTARIS INC (AEZS.CA) currently has 12 employees.
AETERNA ZENTARIS INC (AEZS.CA) has a resistance level at 4.13. Check the full technical report for a detailed analysis of AEZS.CA support and resistance levels.
The Revenue of AETERNA ZENTARIS INC (AEZS.CA) is expected to decline by -2.27% in the next year. Check the estimates tab for more information on the AEZS.CA EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
AEZS.CA does not pay a dividend.
AETERNA ZENTARIS INC (AEZS.CA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-15.41).
ChartMill assigns a fundamental rating of 2 / 10 to AEZS.CA. While AEZS.CA seems to be doing ok healthwise, there are quite some concerns on its profitability.
Over the last trailing twelve months AEZS.CA reported a non-GAAP Earnings per Share(EPS) of -15.41. The EPS decreased by -274.15% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -56.8% | ||
ROE | -139.22% | ||
Debt/Equity | 0.01 |
For the next year, analysts expect an EPS growth of 68.75% and a revenue growth -2.27% for AEZS.CA